Holen Sie sich die Stockscreener-App
90.89
1.53%
1.11
Mirum Pharmaceuticals Inc Aktie (MIRM) Neueste Nachrichten
Aug Patterns: Can Mirum Pharmaceuticals Inc benefit from deglobalization2026 Catalysts & Weekly Breakout Watchlists - baoquankhu1.vn
Does Advancing Brelovitug Into Late-Stage HDV Trials Change The Bull Case For Mirum Pharmaceuticals (MIRM)? - simplywall.st
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The AI Journal
Mirum Pharmaceuticals at Leerink Conference: Strategic Growth Plans By Investing.com - Investing.com Canada
Mirum Pharmaceuticals at Citizens Life Sciences: Strategic Pipeline Advancements By Investing.com - Investing.com Canada
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Understanding the Setup: (MIRM) and Scalable Risk - Stock Traders Daily
Mirum expands into liver diseases with Bluejay Therapeutics acquisition - MSN
Teachers Retirement System of The State of Kentucky Invests $1.08 Million in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals, Inc. (MIRM) earnings expected to grow: What to know ahead of Q4 release - MSN
Mirum’s Brelovitug Phase 3 Milestones Reframe Rare Disease Growth Story - simplywall.st
Mirum Finishes Participant Enrollment and Screening for Liver Disease Research - Bitget
Mirum Completes Enrollment & Screening in Liver Disease Studies - Barchart.com
TD Asset Management Inc Buys Shares of 15,400 Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals provides Azure clinical program update for Brelovitug in chronic hepatitis delta virus - marketscreener.com
Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus - marketscreener.com
Volatility Watch: Is Mirum Pharmaceuticals Inc a stock for growth or value investorsPortfolio Value Report & Real-Time Buy Signal Alerts - baoquankhu1.vn
Evercore ISI raises Mirum Pharmaceuticals stock price target on pipeline progress - Investing.com
Mirum Pharmaceuticals, Inc. (MIRM) Stock Analysis: A Promising Biotech with 35.82% Upside Potential - DirectorsTalk Interviews
William Blair Investment Management LLC Acquires Shares of 313,259 Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Vanguard Group Inc. Sells 19,500 Shares of Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
MIRM Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Mirum Pharmaceuticals (MIRM) Is Down 12.8% After Shelf Filing For US$1.3 Billion Equity Issuance - simplywall.st
HC Wainwright Brokers Decrease Earnings Estimates for MIRM - MarketBeat
Assessing Mirum Pharmaceuticals (MIRM) Valuation After Recent Share Price Volatility - simplywall.st
A Look At Mirum Pharmaceuticals (MIRM) Valuation After Volatile Trading On Common Stock Offering News - Yahoo Finance
Mirum Pharmaceuticals (NASDAQ:MIRM) Downgraded to "Hold" Rating by Wall Street Zen - MarketBeat
Mirum Pharmaceuticals Stock Drops 15% After Share Offering. Analysts Still Target $120 - TIKR.com
Mirum Pharmaceuticals Achieves 104.92% Return, Establishing Itself as a Multibagger Stock - Markets Mojo
Mirum Pharmaceuticals price target raised to $130 from $123 at Morgan Stanley - TipRanks
MIRM Mirum Pharmaceuticals, Inc. Feb 26 2026 Leerink Maintains Outperform - Meyka
Mirum Pharmaceuticals (MIRM) Narrowing Losses Challenge Bearish Profitability Narratives In FY 2025 Results - simplywall.st
Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $117.00 at TD Cowen - MarketBeat
13 Analysts Have This To Say About Mirum Pharmaceuticals - Benzinga
Mirum Pharmaceuticals stock falls on R&D spending outlook, RBC reiterates Outperform - Investing.com Canada
Mirum's Q4 Earnings Lag, Higher Product Sales Drive Y/Y Revenues - Finviz
Evercore ISI reiterates Mirum Pharmaceuticals stock rating at Outperform By Investing.com - Investing.com UK
Royal Bank Of Canada Cuts Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $128.00 - MarketBeat
Mirum Pharmaceuticals (NASDAQ:MIRM) Shares Gap Down Following Weak Earnings - MarketBeat
Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Cut to $132.00 by Analysts at Citizens Jmp - MarketBeat
Mirum Pharmaceuticals (NASDAQ:MIRM) Given New $125.00 Price Target at Stifel Nicolaus - MarketBeat
Mirum Pharmaceuticals: Nothing Stops This Train (But The Technicals) (NASDAQ:MIRM) - Seeking Alpha
RBC Lowers Price Target on Mirum Pharmaceuticals to $128 From $130, Keeps Outperform Rating - marketscreener.com
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update - BioSpace
Mirum Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates - Bitget
Mirum Pharmaceuticals (MIRM) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Mirum Pharmaceuticals Reports Strong Q4 2025 Earnings and 2026 Guidance - Intellectia AI
Mirum Pharmaceuticals Files For Offering Of Up To 8.96 Million Shares Of Common Stock By The Selling Stockholders - TradingView
Mirum (MIRM) Q4 2025 Earnings Call Transcript - AOL.com
According to the latest filing submitted to the U.S. Securities and Exchange Commission (SEC), Mirum Pharmaceuticals, Inc. has officially registered a public offering plan of common stock initiated by selling shareholders. - Bitget
Earnings call transcript: Mirum Pharmaceuticals’ Q4 2025 revenue exceeds expectations - Investing.com
Mirum Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
MIRM: 2025 sales surged 55% to $521M; 2026 guidance set at $630–$650M with major pipeline catalysts - TradingView
Mirum Pharmaceuticals Reports Higher Q4 Revenue - marketscreener.com
Earnings Flash (MIRM) Mirum Pharmaceuticals Posts Q4 Revenue $148.9M, vs. FactSet Est of $142.5M - marketscreener.com
Mirum Pharmaceuticals (NASDAQ:MIRM) Announces Quarterly Earnings Results - MarketBeat
Mirum Pharmaceuticals earnings up next as pipeline readouts loom - Investing.com Nigeria
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):